NCT01645085View on ClinicalTrials.gov

A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

MCC-based 13% drug loaded tablets

50mg tablets, dosed as 2 tablets (100mg total)

DRUG

Mannitol-based 38% drug-loaded tablet

One 100mg tablet

DRUG

MCC-based 13% drug loaded tablets

3 tablets (150mg total)

DRUG

Mannitol-based 38% drug-loaded tablet

One 150 mg tablet

Trial Locations (1)

Unknown

Overland Park

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY